April 22nd 2024
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
No Improvement in OS With Extended Vs Standard Lymphadenectomy in MIBC
June 6th 2023Findings from the phase 3 SWOG S1011 trial highlight no significant differences between extended lymphadenectomy vs standard lymphadenectomy in terms of disease-free survival in patients with muscle-invasive breast cancer.
Enfortumab Vedotin Combo Gets Accelerated FDA Nod for Urothelial Cancer
April 3rd 2023Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.